文献速递胸部肿瘤

人工智能驱动的非小细胞肺癌新辅助阿替利珠单抗治疗病理缓解评估:LCMC3研究结果

Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
PubMed 文献 · J Thorac Oncol · 2023-12-07

LCMC3研究评估可切除非小细胞肺癌患者新辅助阿替利珠单抗治疗后病理缓解。采用指南视觉法和卷积神经网络数字法评估原发肿瘤切除标本中存活肿瘤百分比。数字评估的主要病理缓解与更长无病生存和总生存相关,人工智能数字病理在辅助病理评估方面展现前景。

要点

  • 视觉评估存活肿瘤百分比的组内相关系数为0.87(95%CI:0.84-0.90)。
  • 视觉评估主要病理缓解(≤10%存活肿瘤)的一致性为92.1%(Fleiss kappa=0.83)。
  • 数字评估主要病理缓解与更长无病生存相关(HR=0.30,95%CI:0.09-0.97,p=0.033)。

核心结论

  • 人工智能驱动的数字病理在辅助新辅助非小细胞肺癌临床试验的病理评估方面展现前景。
  • 在临床环境中开发人工智能驱动方法可能帮助病理学家进行临床操作,包括常规病理缓解评估,并进而支持改善患者照护和长期结局。

研究设计与样本

  • LCMC3(NCT02927301)评估可切除非小细胞肺癌患者的新辅助阿替利珠单抗治疗,报告主要病理缓解率为20%。
  • 使用基于指南的视觉技术在原发肿瘤切除标本中测定病理缓解,并开发卷积神经网络模型使用相同标准在全切片图像上数字化测量存活肿瘤百分比。
  • 评估由47名当地病理学家之一对151例进行的视觉存活肿瘤百分比测定与三名中心病理学家之间的的一致性。
  • 数字评估存活肿瘤百分比在136例中进行。

主要发现

  • 视觉存活肿瘤百分比测定的组内相关系数为0.87(95%CI:0.84-0.90)。
  • 原发肿瘤视觉评估≤10%存活肿瘤(主要病理缓解)的一致性为92.1%(Fleiss kappa=0.83)。
  • 数字评估存活肿瘤百分比与视觉评估相关(Pearson r=0.73;数字/视觉斜率=0.28)。
  • 数字评估主要病理缓解预测视觉评估主要病理缓解具有出色区分度(受试者工作特征曲线下面积0.98)。
  • 数字评估主要病理缓解与更长无病生存相关(HR=0.30,95%CI:0.09-0.97,p=0.033)和总生存相关(HR=0.14,95%CI:0.02-1.06,p=0.027),对比无主要病理缓解。

关键数值与推荐

  • 主要病理缓解定义为原发肿瘤视觉评估≤10%存活肿瘤。
  • 视觉存活肿瘤百分比测定的组内相关系数为0.87(95%CI:0.84-0.90)。
  • 视觉评估主要病理缓解的一致性为92.1%(Fleiss kappa=0.83)。
  • 数字评估存活肿瘤百分比与视觉评估的Pearson r=0.73,数字/视觉斜率=0.28。
  • 数字评估主要病理缓解预测视觉评估主要病理缓解的受试者工作特征曲线下面积为0.98。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve the efficiency and precision of PathR assessment. LCMC3 (NCT02927301) evaluated neoadjuvant atezolizumab in patients with resectable NSCLC and reported a 20% major PathR rate. METHODS: We determined PathR in primary tumor resection specimens using guidelines-based visual techniques and developed a convolutional neural network model using the same criteria to digitally measure the percent viable tumor on whole-slide images. Concordance was evaluated between visual determination of percent viable tumor (n = 151) performed by one of the 47 local pathologists and three central pathologists. RESULTS: For concordance among visual determination of percent viable tumor, the interclass correlation coefficient was 0.87 (95% confidence interval [CI]: 0.84-0.90). Agreement for visually assessed 10% or less viable tumor (major PathR [MPR]) in the primary tumor was 92.1% (Fleiss kappa = 0.83). Digitally assessed percent viable tumor (n = 136) correlated with visual assessment (Pearson r = 0.73; digital/visual slope = 0.28). Digitally assessed MPR predicted visually assessed MPR with outstanding discrimination (area under receiver operating characteristic curve, 0.98) and was associated with longer disease-free survival (hazard ratio [HR] = 0.30; 95% CI: 0.09-0.97, p = 0.033) and overall survival (HR = 0.14, 95% CI: 0.02-1.06, p = 0.027) versus no MPR. Digitally assessed PathR strongly correlated with visual measurements. CONCLUSIONS: Artificial intelligence-powered digital pathology exhibits promise in assisting pathologic assessments in neoadjuvant NSCLC clinical trials. The development of artificial intelligence-powered approaches in clinical settings may aid pathologists in clinical operations, including routine PathR assessments, and subsequently support improved patient care and long-term outcomes.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dacic S, Travis WD, Giltnane JM, et al. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study. J Thorac Oncol. 2023. PMID: 38070597. doi:10.1016/j.jtho.2023.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。